The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2019 | The clinical application of MRD testing in AML
Michael Heuser
• 1 Jun 2019
Here, Michael Heuser, MD, of Hannover Medical School, Hanover, Germany, gives a background on the clinical application of measurable residual disease (MRD) testing for acute myeloid leukemia (AML). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
